[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

United Therapeutic (UTHR)

United Therapeutic (UTHR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 24,134,510
  • Shares Outstanding, K 42,447
  • Annual Sales, $ 3,183 M
  • Annual Income, $ 1,335 M
  • EBIT $ 1,436 M
  • EBITDA $ 1,521 M
  • 60-Month Beta 0.60
  • Price/Sales 7.68
  • Price/Cash Flow 17.45
  • Price/Book 4.14

Options Overview Details

View History
  • Implied Volatility 33.34% (+0.96%)
  • Historical Volatility 25.33%
  • IV Percentile 20%
  • IV Rank 10.72%
  • IV High 92.62% on 08/25/25
  • IV Low 26.23% on 06/18/25
  • Expected Move (DTE 33) 38.62 (6.79%)
  • Put/Call Vol Ratio 0.09
  • Today's Volume 440
  • Volume Avg (30-Day) 2,755
  • Put/Call OI Ratio 0.65
  • Today's Open Interest 50,084
  • Open Int (30-Day) 38,819
  • Expected Range 529.96 to 607.20

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $6.90
  • Number of Estimates 5
  • High Estimate $7.48
  • Low Estimate $6.07
  • Prior Year $6.41
  • Growth Rate Est. (year over year) +7.64%

Price Performance

See More
Period Period Low Period High Performance
1-Month
560.16 +1.50%
on 04/24/26
609.35 -6.69%
on 05/06/26
-9.00 (-1.56%)
since 04/15/26
3-Month
466.00 +22.01%
on 02/23/26
609.35 -6.69%
on 05/06/26
+94.92 (+20.04%)
since 02/13/26
52-Week
272.12 +108.94%
on 07/31/25
609.35 -6.69%
on 05/06/26
+264.66 (+87.08%)
since 05/15/25

Most Recent Stories

More News
United Therapeutics Corporation Announces FDA Clearance to Proceed with UHeart Xenotransplantation Clinical Trial

First-ever human clinical trial of a xenoheart intended to support potential registration through the submission of a Biologics License Application to the U.S. FDA

UTHR : 568.58 (-1.25%)
5 Insightful Analyst Questions From United Therapeutics’s Q1 Earnings Call

5 Insightful Analyst Questions From United Therapeutics’s Q1 Earnings Call

UTHR : 568.58 (-1.25%)
United Therapeutics Corporation to Present at the RBC Capital Markets Global Healthcare Conference

United Therapeutics Corporation (Nasdaq: UTHR ) announced today that James Edgemond, Chief Financial Officer and Treasurer, will provide a company overview and update on...

UTHR : 568.58 (-1.25%)
United Therapeutics Corporation Presents New Data from TETON-1, ADVANCE OUTCOMES, and Additional Research in Pulmonary Hypertension and Pulmonary Fibrosis at ATS 2026

Presentations of results from the positive TETON phase 3 pivotal studies of inhaled treprostinil in idiopathic pulmonary fibrosis ( IPF ) include efficacy and safety results from ...

UTHR : 568.58 (-1.25%)
UTHR Q1 Deep Dive: Pipeline Advances and Product Launches Dominate Outlook

UTHR Q1 Deep Dive: Pipeline Advances and Product Launches Dominate Outlook

UTHR : 568.58 (-1.25%)
United Therapeutics (NASDAQ:UTHR) Reports Sales Below Analyst Estimates In Q1 CY2026 Earnings

United Therapeutics (NASDAQ:UTHR) Reports Sales Below Analyst Estimates In Q1 CY2026 Earnings

UTHR : 568.58 (-1.25%)
United Therapeutics: Q1 Earnings Snapshot

United Therapeutics: Q1 Earnings Snapshot

UTHR : 568.58 (-1.25%)
United Therapeutics Corporation Reports First Quarter 2026 Financial Results

United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, today announced its financial results for the quarter ended March 31, 2026. Total revenues in the first quarter...

UTHR : 568.58 (-1.25%)
MannKind Announces Ralinepag Dry Powder Inhalation (DPI) Program to be Pursued for Pulmonary Hypertension and Fibrotic Lung Diseases

The formulation is being developed in collaboration with United Therapeutics Corporation  United Therapeutics made an additional $5 million payment to MannKind to support the rapid advancement of ralinepag...

MNKD : 3.09 (-4.04%)
UTHR : 568.58 (-1.25%)
United Therapeutics Reports Tomorrow With Wall Street Already Bracing for Margin Pressure

Barchart Research What to Expect from UTHR Earnings UTHR Generated May 5, 2026 Current Price $572.20 EPS Estimate $$6.73 Consensus Rating Moderate Buy Average Move 7.25% United Therapeutics Reports Tomorrow...

UTHR : 568.58 (-1.25%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed below 50%. The market is indicating support for a bearish trend.

See More Share

Business Summary

United Therapeutics Corporation markets four medicines in the United States to treat pulmonary arterial hypertension (PAH): Remodulin, an injectable formulation of treprostinil, Orenitram, an oral version of treprostinil, Tyvaso, an inhaled version of treprostinil, and Adcirca (tadalafil; also sold by...

See More

Key Turning Points

3rd Resistance Point 586.19
2nd Resistance Point 581.34
1st Resistance Point 574.96
Last Price 568.58
1st Support Level 563.73
2nd Support Level 558.88
3rd Support Level 552.50

See More

52-Week High 609.35
Last Price 568.58
Fibonacci 61.8% 480.53
Fibonacci 50% 440.73
Fibonacci 38.2% 400.94
52-Week Low 272.12

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.